Two Stocks you Can Bet on: HCP, Inc. (NYSE:HCP), The Goldman Sachs Group, Inc. (NYSE:GS)

HCP, Inc. (NYSE:HCP) kept active in under and overvalue discussion, HCP holds price to book ratio of 1.53 that presents much better indicator to find market price of a share price over its book value of equity for investment valuation.

HCP (HCP) reported that Peter Scott will join the company as Executive Vice President and CFO, effective February 13, 2017.  Mr. Scott succeeds Tom Herzog who was appointed Chief Executive Officer in January 2017. “On behalf of our Board, Executive Chairman Mike McKee and the rest of the management team, I am excited to welcome Pete to HCP,” said Tom Herzog, the CEO of HCP. “We know Pete well.  We have worked closely with him and have consistently been impressed with his work ethic, insights and analytical skills.  His deep health care real estate, capital markets and transaction experience are highly complementary to the executive team we have assembled.”

Fundament/ News Factor in Focus

Taking look on ratio analysis, HCP has forward price to earnings ratio of 35.38. The co is presenting price to cash flow as 105.88, the low single digit may indicate stock is undervalued and vice versa. On other hand, keeping in mind stable cash flows but few growth prospects make traders to value lower.

The firm has price volatility of 2.04% for a week and 1.93% for a month. Its beta stands at 0.26 times. Narrow down four to firm performance, its weekly performance was -0.86% and monthly performance was 3.65%.

The Goldman Sachs Group, Inc. (NYSE:GS) runs in leading trade, it inching down -0.11% to traded at $233.65. GS attains analyst recommendation of 2.50 on scale of 1-5 with week’s performance of 0.53%.

To find out the technical position of GS, it holds price to book ratio of 1.28 that unearth high-growth companies selling at low-growth prices, but it requires appropriate measurement approach. It has forward price to earnings ratio of 10.74, and price to earnings ratio calculated as 14.30. The price to earnings growth ration calculated as 1.13.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 34.20%, and looking further price to next year’s EPS is 13.82%. While take a short look on price to sales ratio, that was 2.46 and price to earning ration of 14.30 attracting passive investors.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *